Sign-up for our newsletter
Protocols & Methods
Reagents & Resources
IMPC / KOMP Data
DiaComp Funded Abstracts
Pilot & Feasibility
Pilot & Feasibility Program Application Abstract
The role of neuropilin 2 in urinary & gastrointestinal complications in diabetes
Pilot & Feasibility Program
Type 2 diabetes (T2D) is associated with significant complications that affect the normal function of the urinary and gastrointestinal tracts. The impact of aberrant bladder and/or gut motility ranges from discomfort in the case of urinary incontinence and diarrhea to life-threatening situations such as intestinal pseudo-obstruction. In spite of this significant healthcare burden, the mechanisms that underlie the development of bladder and GI dysmotility in diabetes, and the extent to which they can be reversed pharmacologically, are incompletely understood. As a result, the development of treatments to address smooth muscle dysmotility in diabetes has been hampered. Coordinated smooth muscle activity is central to the normal function of the bladder and gastrointestinal tracts, underlying both their storage and voiding/expulsion capabilities. Data from our group have identified a new function for neuropilin 2 (Nrp2) in regulation of smooth muscle. Deletion of Nrp2 in led to an increase in evoked contraction of bladder strips or colonic rings, but slower gastrointestinal transit. In mice with diminished bladder contractility secondary to partial bladder outlet obstruction, inducible SM-specific deletion of Nrp2 was found to restore SM contractility relative to Nrp2-intact mice. In this proposal, we hypothesize that Nrp2-regulated signaling is a novel, accessible target to control dysregulated smooth muscle activity in diabetes. We will test the hypothesis with the following Specific Aims: (1) Determine the impact of Nrp2 targeting on bladder and gut contractility in diabetes. (2) Interrogate neuropilin 2-regulated signaling networks in diabetes. We will employ functional analyses of bladder and gastrointestinal contractility and motility in mice with type II diabetes. We will delete Nrp2 in vivo using a CreLox approach to understand how bladder and gut contractility are influenced by Nrp2 deletion, in the context of diabetes. We will also employ a multiomics approach to interrogate the molecular basis of the physiological alterations observed in bladder and gut in diabetes. At the end of the project period, we will understand the extent to which manipulation of Nrp2 signaling restores the contractile capability of smooth muscle in the urinary and gastrointestinal tracts in diabetes, and the associated signaling networks that lie downstream of Nrp2. Successful completion of the studies would highlight the potential for therapeutic targeting of Nrp2 and its effectors in the context of diabetes.
Data for this report has not yet been released.
Welcome to the DiaComp Login / Account Request Page.
Note: Passwords are case-sensitive.
Please save my Email Address on this machine.
Not a member?
If you are a funded DiaComp investigator, a member of an investigator's lab,
or an External Scientific Panel member to the consortium, please
request an account.
Forgot your password?
Enter your Email Address and
There was a problem with the page:
Safari Browser Detected...
We strive to make the DiaComp site compatable with as many browsers as possible, but some of our third party tools don't work with the Safari browser.
In order to explore this site we highly recommend using the most recent versions of the following browsers:
© 2018 DiaComp.org
All rights reserved
Please acknowledge all posters, manuscripts or scientific materials that were generated in part or whole using funds from the Diabetic Complications Consortium(DiaComp) using the following text:
Financial support for this work provided by the NIDDK Diabetic Complications Consortium (RRID:SCR_001415, www.diacomp.org), grants DK076169 and DK115255
Citation text and image have been copied to your clipboard. You may now paste them into your document. Thank you!